Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8962267
SERIAL NO

13138843

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a method for determining or predicting the response of a patient diagnosed with non small cell lung cancer to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non small cell lung cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples of said patients.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
STICHTING HET NEDERLANDS KANKER INSTITUUT1066 CX AMSTERDAM

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
De, Wijn Richard Nijmegen, NL 10 11
Hilhorst, Maria Helena Wageningen, NL 8 64
Klomp, Houke Marian Amsterdam, NL 1 2
Ruijtenbeek, Robby Utrecht, NL 17 45
Van, Den Heuvel Michael Maria Amsterdam, NL 1 2

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 24, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00